Import from '@womanrx/components'

Repatha (Evolocumab) Seasonal Use: What Every Woman Needs to Know

Why Seasons Matter for Women on Repatha

Seasonal variation in lipids is real, measurable, and clinically meaningful for women on evolocumab. LDL cholesterol rises predictably in colder months in population studies, with winter peaks averaging 4 to 8 mg/dL above summer troughs. For a woman already near her LDL target on Repatha, that swing may push her back above goal without any change in adherence or diet.

The reasons are multiple. Physical activity drops in winter. Dietary fat intake increases around holiday periods. Vitamin D levels fall, and emerging evidence links low vitamin D to modestly higher LDL in women. Estrogen also fluctuates across seasons in ways that are not yet well characterized, though perimenopausal women are most vulnerable to lipid destabilization because their estrogen is already erratic.

A woman managing heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) cannot afford to assume her late-autumn LDL panel reflects her year-round status.

The Winter LDL Problem in Women

A systematic analysis of seasonal lipid variation found that total cholesterol peaks in winter in the Northern Hemisphere, with the pattern more pronounced in women than men. Post-menopausal women showed the steepest winter rise, likely because they lack the estrogen-related buffer that keeps LDL lower in premenopausal years. If your most recent lipid panel was drawn in January, your summer LDL may actually be meaningfully lower. Timing your monitoring labs in spring and autumn gives a more representative picture.

How Estrogen Shapes Your Baseline LDL

Before menopause, endogenous estrogen upregulates LDL receptors in the liver, lowering circulating LDL. After natural menopause, LDL rises an average of 10 to 14 mg/dL within the first two years of the transition. Women with FH who were previously "controlled" on statin alone may cross the threshold for needing Repatha specifically at perimenopause, not because treatment failed but because their physiology changed. That menopausal LDL spike tends to be worst in the first winter after menopause begins.

Repatha Pharmacology: What the Drug Actually Does

Evolocumab is a fully human IgG2 monoclonal antibody that binds and inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the hepatocyte surface, clearing more LDL from the bloodstream. The drug reduces LDL-C by approximately 60% from baseline when added to maximally tolerated statin therapy.

FOURIER Trial: What the Evidence Actually Shows for Women

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD and randomly assigned them to evolocumab or placebo on top of statin therapy. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% in the evolocumab group over a median 2.2 years of follow-up.

The critical sex-specific caveat: women represented only approximately 25% of the FOURIER population, roughly 6,900 participants. A pre-specified sex-stratified subgroup analysis of FOURIER showed directionally consistent benefit in women, but the confidence intervals were wider, reflecting the smaller female sample. Direct female-specific efficacy data are therefore extrapolated from a population that was three-quarters male. This is a genuine evidence gap, and you deserve to know it.

A Clinical Framework for Women-Specific PCSK9 Monitoring

Because the trial data skews male and because women's LDL physiology shifts with hormonal status, WomanRx recommends a four-point seasonal monitoring approach for women on evolocumab:

1. Draw a lipid panel in late October or November to capture the winter peak before it becomes a missed escalation opportunity.
2. Repeat in April or May to confirm whether summer trough is at target.
3. At perimenopause onset, treat the lipid panel as if it is a new baseline, because it effectively is.
4. If dose is 140 mg every two weeks and winter LDL remains above the individualized target (typically <70 mg/dL in established ASCVD, <100 mg/dL in primary prevention HeFH), discuss switching to 420 mg monthly dosing with your clinician before attributing the result to non-response.

Storage Across Seasons: The Details That Actually Matter

Repatha is a biologic. Heat and freezing both degrade the protein structure and reduce potency. The manufacturer-specified storage range is 2°C to 25°C (36°F to 77°F). The drug may be kept at room temperature (up to 25°C/77°F) for a maximum of 30 days in the original carton, protected from light. After that 30-day window, the pen or prefilled syringe must be discarded even if refrigeration was restored.

Summer Heat: Your Highest-Risk Season for Storage Failure

Summer creates two distinct storage threats. The first is indoor heat: a car glove compartment on a 90°F day can exceed 130°F within minutes, far above the drug's upper limit. The second is shipping: mail-order pharmacy shipments during a heat wave arrive in insulated packaging, but that packaging typically maintains temperature for only 24 to 48 hours. If your package sits on a doorstep for several hours in July, the drug may be compromised even if it looks normal.

Practical rules:

• Never leave Repatha in a car, even briefly, from May through September in most of the United States.
• Schedule mail-order deliveries for days when you are home, or request ship-to-pharmacy during summer months.
• If a pen was exposed to temperatures above 25°C for an unknown duration, do not use it. Contact your pharmacy for a replacement and note the exposure in writing for insurance documentation.

Winter Cold: Freezing Is a Different Risk

Freezing destroys the biologic matrix. The FDA prescribing information explicitly states that Repatha must not be frozen and that a frozen-then-thawed pen should be discarded. A garage refrigerator set too cold, or a package left on a doorstep overnight in January when temperatures drop below 32°F, can silently freeze and deactivate your dose. If you store Repatha in a spare refrigerator, verify its temperature with a thermometer quarterly. Many garage refrigerators run colder than their display indicates, especially in winter.

Who Repatha Is Right For: A Women's Life-Stage Guide

Premenopausal Women with FH or Early ASCVD

If you are of reproductive age, the first conversation before starting Repatha must address contraception. The drug is contraindicated in pregnancy. If you have heterozygous or homozygous FH and have not yet reached cardiovascular endpoints, your treating clinician should confirm that your statin plus any other lipid-lowering therapy is genuinely maximally tolerated before adding a PCSK9 inhibitor, following ACC/AHA guideline thresholds.

Oral combined hormonal contraceptives raise LDL slightly in some women and raise triglycerides; this interaction is worth checking at your first lipid panel after starting hormonal contraception. It does not necessarily require stopping the contraceptive, but it does mean interpreting the panel with that context.

Perimenopausal Women

Perimenopause is the highest-risk transition window for lipid deterioration in women who were previously well controlled. LDL-C trajectories in the SWAN (Study of Women's Health Across the Nation) cohort showed that LDL increases most steeply in the two years before and two years after the final menstrual period. If you were on statin-only therapy through your forties and your LDL has now climbed despite adherence, perimenopause is a plausible cause before assuming statin failure.

Repatha added to statin in this group can close the gap that hormone-related LDL rise creates. Menopausal hormone therapy (MHT) with estradiol does modestly lower LDL and raise HDL, but it is not a lipid-lowering drug and does not replace PCSK9 inhibition in high-risk women.

Post-Menopausal Women with Established ASCVD

This is the group with the highest absolute cardiovascular risk and therefore the largest absolute benefit from LDL lowering, even though relative risk reduction in FOURIER was similar across age groups. Absolute MACE risk in post-menopausal women with established ASCVD is substantially higher than in age-matched premenopausal women, which means the number needed to treat is lower and the benefit-to-cost calculation favors treatment more strongly.

Post-menopausal women are also more likely to experience statin-associated muscle symptoms (SAMS), partly because lower estrogen may affect mitochondrial function in muscle. If SAMS prevented you from reaching a high-intensity statin dose, Repatha becomes a particularly attractive option as it does not cause myopathy.

Women for Whom Repatha Is Not the Right Choice Right Now

• Pregnant or planning pregnancy in the next cycle (see section below).
• Breastfeeding (insufficient safety data).
• Women whose LDL has not been tested on maximally tolerated statin plus ezetimibe first, per ACC/AHA guidelines, unless LDL is severely elevated (>190 mg/dL in HoFH or HeFH with additional risk factors).
• Women with a latex allergy using the autoinjector (the needle cover contains dry natural rubber).

Pregnancy, Lactation, and Contraception: Required Reading

Evolocumab is not approved for use in pregnancy and should be discontinued before conception.

Pregnancy Safety Data

There are no adequate, well-controlled studies of evolocumab in pregnant women. Animal reproductive studies showed that evolocumab at doses 12 times the human clinical exposure caused fetal skeletal abnormalities in cynomolgus monkeys. PCSK9 is expressed in the placenta and may play a role in fetal lipid metabolism, which means blocking it during organogenesis carries biologically plausible risk. Because IgG antibodies cross the placenta, particularly in the second and third trimesters, fetal exposure is expected if a woman continues the drug into pregnancy.

The FDA prescribing information classifies evolocumab under the current labeling system as having insufficient human data to establish safety, with animal data suggesting risk. The practical guidance from the label: if a patient becomes pregnant while on Repatha, the drug should be stopped immediately, and the patient should be referred to a maternal-fetal medicine specialist given the underlying FH or ASCVD diagnosis.

Contraception Requirements

Because evolocumab has a half-life of approximately 11 to 17 days, residual drug levels persist for roughly two months after the last dose. Women of reproductive potential should use reliable contraception during treatment and for at least 60 days after the final injection. This applies even if doses are only monthly. Discuss the specific contraceptive method with your clinician, particularly if you are also on statins that interact with certain hormonal contraceptives.

Lactation

It is unknown whether evolocumab transfers into human breast milk. IgG antibodies are present in colostrum and breast milk, and given the molecular weight and IgG class of evolocumab, some transfer is theoretically possible. The FDA label advises clinicians to weigh the developmental and health benefits of breastfeeding against the mother's need for the drug and potential adverse effects on the infant. Given the non-urgent nature of most lipid-lowering therapy in the postpartum window, most clinicians choose to defer Repatha until breastfeeding is complete.

Postpartum Return to Therapy

Women with homozygous FH face a more difficult calculation, as their LDL without treatment can exceed 400 mg/dL and the cardiovascular risk of treatment interruption is substantial. In this subset, the postpartum period (once breastfeeding ceases) should prompt immediate restarting of the full PCSK9 inhibitor regimen, with lipid panel confirmation within four weeks of the first post-delivery dose.

The Menstrual Cycle, Hormonal Contraceptives, and Lipid Variability

Lipid levels in premenopausal women are not static across the cycle. LDL-C is lowest in the follicular phase and rises slightly in the luteal phase, with differences of approximately 5 to 10 mg/dL between phases in some studies. This within-cycle variability is large enough that a single lipid panel drawn at an unknown cycle day can misrepresent a woman's true average LDL. For women on Repatha, this matters when evaluating whether the drug is working. A practical recommendation: draw your monitoring lipid panel on day 3 to 7 of the cycle (early follicular phase) for the most reproducible result. If you no longer menstruate, this consideration does not apply.

Combined oral contraceptives containing levonorgestrel or norethindrone can raise LDL by 5 to 15 mg/dL, while drospirenone-containing pills tend to be lipid-neutral or mildly favorable. If your LDL appears higher than expected on Repatha, ask your clinician whether your contraceptive formulation might be contributing before concluding the drug is insufficient.

Dosing, Injection Technique, and the Season-Specific Injection Comfort Issue

Standard dosing is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly. The 420 mg monthly dose requires either three consecutive 140 mg autoinjector pens injected within 30 minutes or a single 420 mg SureClick autoinjector. Both regimens produce equivalent LDL lowering.

Cold-Weather Injection Tips

Injecting cold medication is more painful and may cause localized reactions. In winter, remove the pen from the refrigerator 30 minutes before injection so it reaches room temperature. Do not warm it in warm water or a microwave. The abdomen, thigh, and upper arm are the three approved injection sites. Rotating sites prevents lipodystrophy, which can affect drug absorption. Women who also inject insulin or GLP-1 receptor agonists should map out a formal rotation schedule to avoid overlapping sites.

Injection-Site Reactions in Women

Injection-site reactions occurred in approximately 3.2% of evolocumab-treated patients in FOURIER, roughly twice the rate seen with placebo. Whether this rate differs by sex was not specifically reported in the published subgroup analyses. Women with thinner subcutaneous tissue (common in older post-menopausal women with lower body fat) may experience more pronounced local bruising.

Monitoring: What Labs to Check and When

For women on Repatha, the minimum monitoring schedule is a fasting lipid panel at baseline, four to twelve weeks after starting or dose-changing, and then every three to twelve months depending on stability. The ACC/AHA 2018 guideline on management of blood cholesterol recommends confirming LDL response at six to eight weeks after initiation.

Given the seasonal LDL variability discussed above, a spring panel and an autumn panel each year is a reasonable clinical standard for women. A clinician seeing only a summer panel may underestimate winter cardiovascular risk; a clinician seeing only a winter panel may falsely conclude the drug is insufficient.

Additional monitoring points specific to women:

• Thyroid function (TSH) annually, as hypothyroidism is eight times more common in women than men and is an independent cause of elevated LDL that can masquerade as statin or PCSK9 inhibitor failure.
• Fasting glucose or HbA1c yearly, as PCSK9 inhibitors have a small but statistically significant association with new-onset diabetes (absolute risk increase of approximately 0.1% per year in FOURIER), and women with PCOS or insulin resistance have a higher baseline diabetes risk.
• Liver enzymes are not routinely required for Repatha (unlike statins), but checking them once at baseline is reasonable if a woman is also on a hepatotoxic medication.

Adherence Across the Year: The Practical Obstacles

Missing a Repatha dose has measurable consequences. The drug's LDL-lowering effect is fully present only when plasma drug levels are maintained. A dose missed by more than three to four days on the every-two-week schedule will produce a measurable LDL rebound. PCSK9 levels rebound sharply within days of a missed dose, because the drug does not durably silence the PCSK9 gene (unlike inclisiran, a small interfering RNA that works differently).

Season-specific adherence threats include:

• Summer travel: a woman who travels internationally should carry Repatha in a medical travel cooler with a logged temperature record. Documentation of refrigerated transport is sometimes required for insurance reimbursement.
• Holiday periods: December and January have the highest rates of missed specialty pharmacy refills across all injectable biologics. Set an automated refill one week before you expect to run out, not on the day the last pen is used.
• Illness: Repatha does not require dose adjustment or discontinuation during minor illness. Women who pause during a winter respiratory infection out of caution are making an unnecessary and potentially harmful decision.

A final practical note: if you have confirmed ASCVD and your LDL on maximally tolerated statin plus ezetimibe remains above 70 mg/dL, the 2022 ACC Expert Consensus Decision Pathway supports PCSK9 inhibitor initiation regardless of season. Do not wait for a "better" lipid panel in spring before seeking authorization.